Nycomed files COPD treatment Daxas in the EU
This article was originally published in Scrip
Executive Summary
Nycomed has filed its chronic obstructive pulmonary disease (COPD) treatment, Daxas (roflumilast), for EU marketing, and is preparing a submission for the US.